

# Investigation Report on China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2021-2025

<https://marketpublishers.com/r/I738AA974F92EN.html>

Date: May 2021

Pages: 50

Price: US\$ 2,600.00 (Single User License)

ID: I738AA974F92EN

## Abstracts

Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) is an effective drug for the prevention and treatment of neutropenia or deficiency caused by tumor radiotherapy or chemotherapy. Its product was first developed by Amgen in the United States. In 2012, PEG-rhG-CSF was approved in China. By 2020, the main manufacturers of PEG-rhG-CSF in China are Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd. and Qilu Pharmaceutical Co., Ltd.

According to CRI's market research, the sales of PEG-rhG-CSF in the Chinese market have increased year by year from 2016 to 2020. Among them, the sales growth in 2017 was the most obvious, from CNY126 million in 2016 to CNY449 million in 2017, with an annual growth rate of 256.08%. The main reason for the sharp increase is that PEG-rhG-CSF was included in China Medical Insurance in 2017 and the approval of indication was leukemia. The price reduction led to a large increase in sales. The CAGR of sales of PEG-rhG-CSF is about 97.58% from 2016 to 2020.

CRI analyzes that the sales volume of PEG-rhG-CSF will keep a growth trend from 2021 to 2025 due to the rapid increase in the number of patients. In China, about 40,000 leukemia patients are newly diagnosed every year. This situation led to a growth in the sales volume of PEG-rhG-CSF, which has the advantages of convenience, stability, high efficiency, and approval of indications. In addition, due to the use of PEG-rhG-CSF for non-medullary malignant tumors, the number of indications approved for China's medical insurance is likely to rise, and the sales and the sales volume will also have the potential to grow.

Topics Covered:

The impact of COVID-19 on China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market

Sales value of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2016-2020

Competitive landscape of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market

Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China

Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China by regions and manufacturers

Analysis on factors affecting the development of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market

Prospect of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market from 2021 to 2025

## Contents

### **1 RELEVANT CONCEPTS OF PEGYLATED RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR (PEG-RHG-CSF)**

- 1.1 Indications for Pegylated Recombinant Human Granulocyte Colony Stimulating Factor
- 1.2 Development of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China
- 1.3 Governmental Approval of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China
- 1.4 The Impact of COVID-19 on Pegylated Recombinant Human Granulocyte Colony Stimulating Factor sales in China

### **2 SALES OF PEGYLATED RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR IN CHINA, 2016-2020**

- 2.1 Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor
  - 2.1.1 Overall Sales Value
  - 2.1.2 Sales Value by Regions
- 2.2 Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor
  - 2.2.1 Overall Sales Volume
  - 2.2.2 Sales Volume by Regions
- 2.3 Sales of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor by Dosage Form in China, 2016-2020
  - 2.3.1 Injection
  - 2.3.2 Analysis of Other Dosage Forms

### **3 ANALYSIS OF MAJOR PEGYLATED RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR MANUFACTURERS IN CHINA, 2016-2020**

- 3.1 Analysis of Market Share of Major Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Manufacturers
  - 3.1.1 Investigation on Market Share by Sales Value
  - 3.1.2 Investigation on Market Share by Sales Volume
- 3.2 Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd.
  - 3.2.1 Enterprise Profile

3.2.2 Sales of Jinyouli (Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd.'s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor) in China

3.3 Qilu Pharmaceutical Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Xinruibai (Qilu Pharmaceutical Co., Ltd.'s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor) in China

## **4 PRICES OF PEGYLATED RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR FOR DIFFERENT MANUFACTURERS IN CHINA, 2020-2021**

4.1 Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd. (Yinish)

4.2 Qilu Pharmaceutical Co., Ltd. (Xinruibai)

## **5 PROSPECT OF CHINESE PEGYLATED RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR MARKET, 2021-2025**

5.1 Influential Factors of Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Development

5.1.1 The Impact of COVID-19 on Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

## List Of Charts

### LIST OF CHARTS

- Chart Patent Information About Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection Registration in China
- Chart Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection over the World
- Chart Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection in China, 2016-2020
- Chart Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection in China by Regions, 2016-2020
- Chart Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection in China, 2016-2020
- Chart Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection in China by Regions, 2016-2020
- Chart Market Share by Sales Value of Top Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Manufacturers in China, 2016-2020
- Chart Sales Value and Volume of Yinish in China, 2016-2020
- Chart Sales Value and Volume of Xinruibai in China, 2016-2020
- Chart Referential Prices of Yinish in China by Regions, 2020-2021
- Chart Referential Prices of Xinruibai in China by Regions, 2020-2021
- Chart Forecast on Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China, 2021-2025
- Chart Forecast on Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China, 2021-2025

## I would like to order

Product name: Investigation Report on China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2021-2025

Product link: <https://marketpublishers.com/r/l738AA974F92EN.html>

Price: US\$ 2,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l738AA974F92EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

